Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
Milestone Pharmaceuticals Price Performance
Shares of NASDAQ MIST opened at $1.31 on Monday. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The business’s 50 day moving average price is $1.38 and its two-hundred day moving average price is $1.73. The company has a market cap of $70.04 million, a PE ratio of -1.62 and a beta of 0.86. Milestone Pharmaceuticals has a twelve month low of $0.63 and a twelve month high of $2.75.
Analyst Ratings Changes
Several brokerages have issued reports on MIST. Cowen downgraded Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 1st. TD Cowen lowered Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 1st. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a research report on Friday, March 28th. Finally, TD Securities lowered shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 1st. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Milestone Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $17.00.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
See Also
- Five stocks we like better than Milestone Pharmaceuticals
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Quality Stocks You Can Buy At a Discount
- What is the FTSE 100 index?
- ExxonMobil: Production Offset Prices, Capital Return Safe in 2025
- Consumer Discretionary Stocks Explained
- Rocket Lab Braces for Q1 Earnings Amid Soaring Expectations
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
